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ABSTRACT Analysis of the major histocmpatibility com-
plex class II gene promoter DRA has previously identified at
least five cis-acting regions required for maximal expression. We
have exmned theDRA promoter for protein-DNA interactions
in the intact cell, which may mediate transcriptional activation.
Using in vivo genomic footprinting we identified interactions in
B-cell lines at the octamer site and the Y, Xl, and X2 boxes. Class
H antigen expressing T-ceD lines maintained contacts identical to
B-cell lines, while class li-negative T-ceDf lines exhibited no
interactions. In lymphoid cell lines, the octamer site is occupied
and required for maximal expression. This is most likely due to
the presence ofthe lymphoid-specific OTF-2 factor. In contrast,
the class iI-positive nonlymphoid glioblastoma cell line does not
exhibit interactions at the octamer site despite the presence ofthe
ubiquitous OTF-1 factor and an open binding site. Thus, the
DRA promoter discriminates ag st OTF-1 activation at the
level of DNA binding in the glioblastoma line. Interferon y
induces class H expression in this gabla cell line and, in
parallel, up-regulates X1 and X2 box protein-DNA interactions,
while all other interactions remain unchanged. These results
suggest that interferon y functions on a poised promoter by
altering weak, nonproductive interactions at the X boxes to
strong interactions. These findis provide direct in vivo evi-
dence to strongly suggest that the modulation of X1 and X2
interactions is an important constituent of the interferon v
induction pathway.
The major histocompatibility complex (MHC) class II mol-
ecules play a central role in the immune response. MHC class
II molecules can present antigen on the surface of cells,
which is then recognized by the T-cell receptor of class
IT-restricted T cells (1, 2). This interaction leads to an
activation ofT cells and the initiation ofan immune response.
The intensity of the response is modulated by the level of
MHC class II molecules on the cell surface (3, 4). Specific
haplotypes of class II have been linked to several autoim-
mune diseases (5). Thus, a detailed investigation of the
regulation of MHC class TI antigen expression is critical to
our understanding of the immune response and immune
system dysfunction. Class H molecules are expressed on a
select group of cell types including B cells, dendritic cells,
thymic epithelial cells, skin Langerhans cells, liver Kupffer
cells, brain glial cells (6-8), and activated macrophages and
T cells (9-12). Cytokines such as interferon y (IFN-y) can
induce class II expression in a small number of class II-
negative cell types (13-16). In most cases, class II expression
is regulated primarily at the level of transcription, prompting
extensive study of the promoter regions and in particular the
HLA-DRA promoter.
University of North Carolina at Chapel
Two highly conserved promoter domains termed the X and
Y boxes lie within the proximal promoter region of class II
genes (17). These elements are critical for optimal class II gene
expression (18-21). The X box interacts in vitro with at least
two proteins, RF-X and hXBP-1. RF-X binds over the 5' end
of the X box (X1) and has aberrant binding in cells from
patients with the bare lymphocyte syndrome (22, 23). hXBP-1
binds at the 3' end of the X box (X2) and has homology to Fos
and Jun (24). Functional analysis with site-specific mutations
has indicated that both X1 and X2 are important for the
constitutive level of transcription and XI is involved in IFN-y
inducibility (24, 25). The Y box contains an inverted CCAAT
motifwith which several proteins have been shown to interact
in vitro. YEBP was partially purified in our laboratory from
B-cell extracts and activates the DRA promoter in vitro (20).
YEBP may be the human analog to the murine NF-Y A/B (26,
27). YB-1 was cloned from an expression library and, while its
DNA recognition site is similar to those ofYEBP and NF-Y,
the expression of YB-i is inversely correlated to the level of
class II expression, implying a potential role as a negative
regulator (28). In addition to the X and Y boxes, the DRA
promoter is unique within the class II family in the presence
of an octamer binding site between the Y and TATA boxes.
This site is functionally required in B cells but not in most
nonlymphoid cell types (18, 29, 30). In addition, a less-
conserved functional domain, W, lies upstream of the X box.
Functional analysis of this region has identified a Servenius
sequence (S), which is required for IFN-y responsiveness
(31-33).
In vitro protein-DNA studies are limited because they may
not accurately reflect the in vivo state of promoter interac-
tions. The recent improvement of the in vivo genomic foot-
printing procedure (34) permits analysis of protein-DNA
interactions in intact cells. This report utilizes in vivo ge-
nomic footprinting to confirm initial findings in B cells (35)
and expands it to class II-positive and class II-negative T-cell
lines. Analysis of an inducible, nonlymphoid cell line re-
vealed the selective lack of interaction at the octamer site
despite the availability of the ubiquitous octamer binding
factor OTF-1 and an open binding site. Most importantly, this
analysis demonstrated that IFN-y induction of class II anti-
gen expression is characterized by an up-regulation ofX1 and
X2 box interactions.
MATERIALS AND METHODS
Cell Lines, Reagents, and DNA Constructs. Raji and Na-
malwa are human Burkitt lymphoma B-cell lines that express
Abbreviations: MHC, major histocompatibility complex; IFN-y,
interferon y; T-LCL, T-lymphoblastoid cell line; B-LCL, B-lympho-
blastoid cell line; CAT, chloramphenicol acetyltransferase; DMS,
dimethyl sulfate.
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high levels of class II antigens. H9 (HuT78) was derived from
a human cutaneous T-cell lymphoma and constitutively ex-
presses class II antigens. HSB and Jurkat are T-lymphoblas-
toid cell lines (T-LCLs) that cannot be induced to express
class II antigens. U373-MG is a glioblastoma multiform cell
line (36). The human recombinant IFN-y was a generous gift
of Biogen. The wild-type DRA promoter-chloramphenicol
acetyltransferase (CAT) fusion construct (5'A-152 WT) has
been described (33). The 5'A-152 MUTocta construct was
generated by site-directed mutagenesis (37) and altered oc-
tamer motif from 5'-TTGATTTGCAT-3' to 5'-TTGcgggt-
CAT-3'.
In VivoFootprinting. In vivo methylation of cells and DNA
preparation were as described by Pfeifer et al. (38). The
ligation-mediated, PCR-amplified, in vivo genomic footprint-
ing was as described by Mueller and Wold (34) except the
initial denaturation was for 10 min at 950C and the samples
were resolved on a 6% denaturing polyacrylamide wedge gel.
The primers to reveal the upper strand with the associated
annealing temperature were as follows: upper 1, 5'-AGG-
GACTCCACTTATGGA-3' (600C); upper 2, 5'-TGGGAG-
TCAGTAGAGCTCGGGAGTG-3' (660C); upper 3, 5'-
GAGTCAGTAGAGCTCGGGAGTGAGGCAG-3' (680C).
The primers to reveal the lower strand were as follows: lower




Transfection and CAT Reporter Analysis. Cell lines were
transiently transfected with 10 jug of test plasmid using a
Bio-Rad Gene Pulser electroporation apparatus, and plasmid
expression was assayed by CAT activity as described (19).
CAT activity was resolved on thin-layer chromatography
plates and quantitated with an Ambis Radioanalytic Image
Processor.
Nuclear Extract Preparation and Gel Mobility-Shift Assay.
Nuclear extracts were prepared according to Dignam et al.
(39). The gel mobility-shift assay was performed essentially
as described by Gerster et al. (40) except samples were
resolved on a4% polyacrylamide gel with TGE buffer (25mM
Tris HCl, pH 7.9/190 mM glycine/1 mM EDTA). The probe
was a 30-base-pair synthetic double-stranded oligonucleotide
that encompasses the octamer element of the DRA promoter
and its flanking sequences.
RESULTS
A number of cis-acting DNA elements within the proximal
150 base pairs of the DRA promoter have been previously
described (see Fig. 2). This report directly assays the protein-
DNA interactions at the endogenous DRA promoter by in
vivo genomic footprinting.
In Vivo, the DRA Promoter Maintains Protein-DNA Inter-
actions Across the Class I Box and at the Octamer Site in Class
II-Expressing B-Lymphoblastoid Cells. Most functional anal-
ysis of the DRA promoter has been performed in B-lympho-
blastoid cell lines (B-LCLs), which constitutively express
high levels of class II antigen. Thus, we chose to initially
examine the in vivo protein-DNA interactions in the B-LCLs
Raji and Namalwa. In vivo genomic footprinting reveals the
close association ofprotein withDNA in the intact cell by the
protection or enhancement ofdimethyl sulfate methylation of
guanine residues (34, 41). These protections or enhancements
are then displayed as alterations in the intensity of specific
bands in the guanine sequence ladder as compared to depro-
teinized DNA.
Class II antigen expressing B-LCLs displayed a series of
guanine contact points on both the upper and lower strand of
the DRA promoter (Fig. 1; summarized in Fig. 2). Both Raji




















FIG. 1. In vivo genomic footprints of the HLA-DRA promoter in
B- and T-LCLs. (A) Upper strand of the DRA promoter revealed by
using the upper primer set (see Materials and Methods). Control, in
vitro methylated deproteinized DNA; DMS, in vivo methylatedDNA
(dimethyl sulfate). Open circles, protection; solid circles, enhance-
ment. Functionally defined DNA domains are indicated on the left.
Contact points are indicated for the first pair oflanes and are identical
in the B-LCLs Namalwa and Raji and in the T-LCL H9. The class
H-negative Jurkat T-LCL exhibited no protein-DNA contacts. Ap-
proximately 50-60%o protection of the octamer element was consis-
tently observed in Namalwa, Raji, and H9. Note that the Raji and
Namalwa DMS lanes are darker overall than the corresponding
control lanes. The weak octamer protection seen in lane 8 (Jurkat)
was not reproducible. Contact points for the upper strand from
bottom to top are -48, -53, -67, -68, -83, -93, -95, -104, -117,
and -150. (B) Lower strand revealed with lower primer set. Lane
markings are the same as in A. Contact points for the lower strand
from top to bottom are -47, -88, -91, -94, -100, -103, -107, and
-108.
Two protections on the upper strand at -48 and -53 and one
on the lower strand at -47 are located at the octamer
consensus sequence. The lower-strand protection was sig-
nificantly weaker (40-50%o protection in Namalwa cells);
however, it was highly reproducible through several (>5)
independent experiments. The octamer sequence is required
for maximal expression ofDRA in B cells (see below and ref.
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FIG. 2. Schematic of HLA-DRA promoter and in vivo contact
points. Shaded boxes, functionally defined DNA elements; long
arrows, strong protections; short arrows, weak partial protections;
arrowheads, enhancements. Xi and X2 boxes are shown as indepen-
dent regions, although they may be overlapping as depicted in Figs.
1 and 3. Small dots between strands represent 10-base-pair incre-
ments starting from the transcription initiation site.
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ofthe upper strand corresponds to the inverted CCAAT motif
in the Y box. Mutation of these residues has been shown (19,
42) to diminish expression from theDRA promoter. The large
19-base-pair region encompassing the Xi and X2 motifs is
completely protected on the lower strand, with one hyper-
sensitive site at the 3' end. The upper strand also reveals
protections in both X1 and X2, with a hypersensitive site
between the two motifs at -95. Interestingly, a single hy-
persensitive adenosine residue appears on the upper strand
between the X region and the Y box when protein is bound
to these elements. Adenosine hypersensitivity is generated
by an increased accessibility of dimethyl sulfate to the minor
grove of the DNA, perhaps due to a distortion in the
three-dimensional structure. Two additional hypersensitive
adenosine residues were detected upstream of the X region
on the upper strand (-117 and -150). These contact points
are not obviously associated with any currently known in
vitro binding sites; however, gross deletion of the region
diminishes expression in B-LCLs (18, 32, 43).
Class II Negative T-LCLs Lack in Vivo Protein-DNA Inter-
actions While a Class II-Expressing T-LCL Is Indistinguishable
from B-LCLs. Human T lymphocytes are unique in their
ability to express cell-surface class II molecules upon antigen
or mitogen activation (10-12) or human T-lymphotropic virus
type I infection (44). We examined the class II-expressing
T-LCL H9 for in vivo protein-DNA interactions (Fig. 1). The
DRA promoter revealed guanine contact points at the oc-
tamer, Y box, and X1 and X2 motifs, which were indistin-
guishable from the contacts detected in B-LCLs. Thus, it
appears that in human B-LCLs and class II-expressing
T-LCLs the same interactions are important for class II gene
expression. However, many human T-LCLs are class II
negative and cannot be induced to express class II antigens.
Two such class II-negative T-LCLs-Jurkat (Fig. 1) and HSB
(data not shown)-exhibited no detectable protein-DNA
interactions at the DRA promoter. Some experiments with
the Jurkat cell line suggested a weak interaction at the
octamer site (Fig. 1A); however, this was not consistently
reproducible. This result is in stark contrast to the in vitro
binding studies with nuclear extracts from HSB cells (19),
where DNA probes spanning the class II box reveal specific
protein-DNA interactions that are qualitatively indistin-
guishable from the class II-expressing B- or T-LCLs. This
suggests that class II-negative human T-LCLs down-regulate
DRA expression not at the level of individual transcription
factors but rather at the level of chromatin structure.
In Vivo Discrimination Against OTF-1 Binding at an Avail-
able Octamer Consensus Sequence in a Functioning DRA
Promoter. In addition to the constitutive mode of class II
antigen expression, several cell types can be induced to
express class II by treatment with cytokines such as IFN-y.
We examined the human glioblastoma multiform line
U373-MG as an example ofa class II-inducible, nonlymphoid
cell (15). The U373-MG cell line has a low level ofcell-surface
class II-positive cells (10-20%), which is induced to high
levels (70%) by IFN-y (ref. 15; data not shown). A striking
deviation from the observations in class II-positive B- and
T-LCLs was detected at the octamer site (Fig. 3, lanes 2 and
7 vs. lanes 11 and 12). No protections were displayed at the
octamer consensus site on either strand. Moreover, the
octamer site remained vacant even after IFN-'y induction of
DRA transcription at 18 and 24 hr. Identical results were
obtained by using the melanoma cell line Thayer, which is
only 1-2% cell-surface class II positive and is induced to
80-85% by IFN-y (data not shown). This finding prompted us
to examine the functional requirement of this site and the
availability of octamer transcription factors. Functional im-
portance was determined by transient transfection of a min-
imalDRA promoter construct containing either a wild-type or
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FIG. 3. IFN-y induction of class II expression in a glioblastoma
cell line up-regulates X box interactions. In vivo footprinting of the
upper and lower strands of the U373-MG cell line was as indicated
in Fig. 1. Con, in vitro methylated deproteinized DNA. Lanes 0, 4,
18, and 48 hr, in vivo methylatedDNA harvested at the time indicated
after addition of IFN-'y (500 units/ml). Symbols and contact points
are as described in Fig. 1. Namalwa lower strand in vivo footprint is
overexposed to reveal complete protection of the X box region as
compared to weak X box protection at 0 and 4 hr post-IFN-y
induction in the U373-MG cell line. Induced U373-MG cells (18 and
48 hr) were indistinguishable from the B-LCLs except for the lack of
octamer binding.
sequences. The results confirmed a functional requirement of
the octamer site in Raji B-LCL and in H9 T-LCL (Table 1).
However, in U373-MG cells mutation of the octamer site did
not result in a loss of promoter function but instead caused a
minimal (<2-fold) increase in activity. Thus, the functional
importance ofthe octamer site parallels its in vivo occupancy.
A family of transcription factors (OTF) has been identified
that binds to the octamer consensus (45). Nuclear extracts
from Raji, H9, and U373-MG cells were subjected to a gel
mobility-shift assay with aDRA octamer probe to resolve the
OTF family (Fig. 4). The most intense band (band A) corre-
sponds to the ubiquitous OTF-1 factor, according to Gerster
et al. (40), and is present in each cell line. Thus, the lack of
in vivo binding in the U373-MG cells suggests that OTF-1 is
discriminated against by the endogenous DRA promoter
structure in this cell line. A second band (band B), most likely
representing the lymphoid-specific OTF-2 factor, is present
at high levels in Raji cells. Interestingly, in H9 nuclear
extracts a weak but detectable complex comigrates with this
band (band B). However, this band is absent in the U373-MG
cell extracts. The availability of this factor directly corre-
Table 1. Functional analysis of the DRA octamer site
Relative CAT
Cell type Plasmid activity
Raji 5'A-152 WT 1.00 (3.8%)
5'A-152 MUTocta 0.30 + 0.06
H9 5'A-152 WT 1.00 (1.3%)
5'A-152 MUTocta 0.16 + 0.12
U373-MG 5'A-152 WT 1.00 (1.7%)
5'A-152 MUTocta 1.70 ± 0.01
Test plasmids contain the DRA promoter sequences up to -152
fused to the CAT reporter gene. Relative CAT activity is normalized
within each cell line to the 5'A-152 WT construct and average
percentage acetylation is given in parentheses. U373-MG expression
was assayed 48 hr after IFN-y induction. Values represent average
of three independent experiments and Raji and U373-MG results
confirm our previous findings (29).
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FIG. 4. Gel mobility-shift assay reveals a family of OTF factors
binding to the DRA octamer site. Source of the nuclear extract is
indicated above each set of four lanes, which represent increasing
amounts of nuclear extract from 3 to 12 Ag. Band A represents the
OTF-1 complex, which is present in all three extracts. Band B
represents complexes comigrating with OTF-2 and is present in Raji
extracts and weakly in H9 extracts. Band B is absent in the U373-MG
extract. Bands A and B can be blocked by competition with an
oligonucleotide containing the octamer motif (ref. 29; data not
shown). Bands C and D are nonspecific and consistent across all of
the extracts.
sponds to the in vivo occupancy of the octamer site and
provides further credence implicating OTF-2 as the func-
tional factor activating DRA transcription.
ION-y Induction of Class II Expression in a Glioblastoma
Cell Line Is Paralleled by an Up-Regulation of in Vivo Binding
at the X1 and X2 Boxes. Before IFN-y induction, a second
distinction was observed between B-LCLs and the U373-MG
cell line. The guanine residues within the X1 and X2 motifs
were partially visible in the in vivo 0-hr sample (Fig. 3). This
is most clearly revealed on the lower strand. The intensity of
the X region guanine bands is only reduced by =60% com-
pared to the deproteinized control DNA. In contrast, in the
B-LCLs there was a complete protection of the X1 and X2
regions. Contact points in the Y box and upstream region
were similar between the lymphoid and glioblastoma cell
lines. IFN-y treatment of the U373-MG cell line induces a
peak of mRNA accumulation at 18-24 hr, which is primarily
controlled at the transcriptional level (46, 47). At 4 hr, no
changes in the in vivo footprint are observed. However,
concomitant with the up-regulation of class II transcription,
the in vivo footprint of the X region at 18 and 48 hr revealed
a change to complete protection of all of the X region guanine
residues (Fig. 3). The up-regulation of in vivo interaction at
the X region makes this region indistinguishable from the
class II-expressing lymphoid cell lines.
DISCUSSION
Myriad in vitro protein-DNA binding events have been
ascribed to the DRA promoter regions. However, it remains
to be determined whether the in vitro studies accurately
reflect conditions in the intact cell. The analysis described
here provides important insight into the in vivo state of
protein-DNA interactions at the DRA promoter.
B cells constitutively express class II and were used to
define a reference panel of in vivo protein-DNA interactions
in lymphoid cells. The data obtained with B cells in this report
confirm the initial findings on the upper strand of the DRA
promoter by Kara and Glimcher (35). Their results with the
DRA gene identified promoter interactions at the octamer site
and the Y, X1, and X2 boxes. In addition, they found a lack
of all interactions in class II-deficient mutant cell lines
derived from certain bare lymphocyte syndrome patients. In
this report, we have extensively expanded these initial stud-
ies in B-cell lines to include class II-positive and -negative
T-cell lines and an IFN-y inducible, nonlymphoblastoid cell
line.
In B-LCLs and a class II-positive T-LCL, the octamer site
was occupied. This occupancy is most likely associated with
the presence of OTF-2 in lymphoid cells, although the
possibility that OTF-1 occupies this site in conjunction with
other lymphoid-specific factors cannot be excluded at this
time. In contrast, the octamer site was vacant in the non-
lymphoid, glioblastoma cell line. This finding agrees with the
functional analysis showing a requirement for these se-
quences in B-LCLs and a class II-positive T-LCL but not in
the glioblastoma cells (Table 1 and ref. 29). The slight
increase in activity seen in the glioblastoma cells upon
mutation of the octamer site may suggest an uncharacterized
repressive role for this site in nonlymphoid class II-positive
cells. The apparent vacancy of the octamer site in the
glioblastoma cell occurs despite the availability of the ubiq-
uitous OTF-1 factor. Furthermore, the lack of octamer bind-
ing is apparently not due to differences in the adjacent
interactions, since all of the neighboring contact points are
the same between the lymphoid and nonlymphoid cells.
These results provide the first direct evidence that in vivo the
OTF-1 binding interaction is selectively excluded in a func-
tional promoter. One explanation for the exclusion may be
inappropriate contacts between OTF-1 and the other trans-
acting factors present on the promoter in this cell line. At
present, it is unclear whether the exclusion of octamer
occupancy is unique to the glioblastoma cell line or is
common to all nonlymphoid class TI-positive cells.
The in vivo protein-DNA interactions at the Y box and the
Xi and X2 boxes confirm the functional data defining each of
these elements as required for optimal class TI expression. In
B-LCLs and class II-positive T-LCLs, the X boxes were
extensively protected. The contact points are clustered into
two groups. One group lies within the X2 motif with single
hypersensitive guanine residues immediately flanking each
side of the X2 box, suggesting these may be the boundaries
of the X2 interaction. The second cluster lies at the 5' end of
the Xi box corresponding to the putative RF-X interaction
domain. A single unprotected guanine residue between the
two groups suggests that the Xi and X2 boxes are separate
and distinct binding events. The hypersensitive adenosine
residue appearing approximately midway between the X and
the Y boxes suggests that this region of the DNA structure
may be distorted-for example, by DNA bending. This is
compatible with a previous study, which demonstrated a
functional requirement for the stereospecific alignment ofthe
X and Y boxes that was independent of the absolute distance
between the two domains (48). This suggests that the X and
Y box factors are able to bend the intervening DNA to come
in direct or indirect contact. In addition, the hypersensitivity
occurs only in the presence of X and Y box protein-DNA
interactions, suggesting that the putative DNA bend may be
driven by the protein-protein contacts or, alternatively, by
protein-DNA contacts.
The glioblastoma cell line U373-MG can be induced by
IFN-yto express high levels of class 11(15, 32). Before IFN-,y
induction, the interactions at the X1 and Xi boxes are weak
compared to B-LCLs. Concomitant with the induction of
DRA transcription, the X box interactions increase in inten-
sity to levels indistinguishable from B cells. No other changes
are detected during the induction. Identical results were
obtained with the melanoma cell line Thayer, which are
induced to -80%o class II-positive by IFN-y. These results
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indicate that in an inducible cell the DRA gene is poised for
expression with the majority of protein-DNA interactions in
place. However, the X box interactions are weak and poten-
tially nonproductive. IFN-y may induce a modification ofthe
existing X box interactions to make the binding productive
or, alternatively, induce new protein-DNA interactions. Re-
cent results have confirmed an increase in X box binding in
vitro in primary rat astrocytes (33). Interestingly, no contact
points directly attributable to the S site were detected.
Functional analysis of the IFN- y induction has demonstrated
a requirement for the S site. It is possible that the S inter-
action escapes detection by the in vivo footprinting tech-
nique. Alternatively, the S domain may be the site of a
transient binding activity only required in the initial stages of
the IFN-y response. A transient interaction has been recently
demonstrated for the overlapping IFN-a/y response site in
the gene of the guanylate-binding protein (49).
In contrast to the poised promoter detected in the glioblas-
toma cell line prior to induction, the class II-negative T-LCLs
displayed no protein-DNA interactions. Class II-negative
T-LCLs cannot be induced to express DRA and thus do not
maintain a poised promoter. Down-regulation of transcrip-
tion through prevention of all interactions at the promoter,
perhaps by reordering the chromatin structure, would be an
effective mechanism to down-regulate the entire class II
locus.
In summary, B- and T-lymphoid cells expressing the class
II DRA gene, maintain constitutive protein-DNA interac-
tions at the octamer site and the Y, Xi, and X2 boxes.
However, the octamer site is not occupied in the nonlym-
phoid cell line in congruence with lymphoid-specific function
of this site. In addition, there is a dynamic up-regulation ofX
box binding in parallel with the induction of expression by
IFN-y in class II-inducible cell lines.
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